ISDA

Entry Detail

PDB ID:

6PKC

Keywords:

TRANSCRIPTION

Title:

Inhibition of Human Menin by VTP-50469

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Escherichia coli BL21(DE3)

PDB Version:

Deposition Date:

2019-06-29

Release Date:

2019-12-18

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.90 Å

R-Value Free:

0.20

R-Value Work:

0.16

R-Value Observed:

0.17

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Menin,Menin
Mutations:A5T
Chain IDs:A, B
Chain Length:490
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:O00255 Pfam ID:PF05053

Ligand Molecules

OP4

Primary Citation

A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia.

Krivtsov, A.V, Evans, K, Gadrey, J.Y, Eschle, B.K, Hatton, C, Uckelmann, H.J, Ross, K.N, Perner, F, Olsen, S.N, Pritchard, T, McDermott, L, Jones, C.D, Jing, D, Braytee, A, Chacon, D, Earley, E, McKeever, B.M, Claremon, D, Gifford, A.J, Lee, H.J, Teicher, B.A, Pimanda, J.E, Beck, D, Perry, J.A, Smith, M.A, McGeehan, G.M, Lock, R.B, Armstrong, S.A.Show

Cancer Cell 36 660 673.e11 (2019)

PMID: 31821784 DOI: 10.1016/j.ccell.2019.11.001

Abstact

Inhibition of the Menin (MEN1) and MLL (MLL1, KMT2A) interaction is a potential therapeutic strategy for MLL-rearranged (MLL-r) leukemia. Structure-based design yielded the potent, highly selective, and orally bioavailable small-molecule inhibitor VTP50469. Cell lines carrying MLL rearrangements were selectively responsive to VTP50469. VTP50469 displaced Menin from protein complexes and inhibited chromatin occupancy of MLL at select genes. Loss of MLL binding led to changes in gene expression, differentiation, and apoptosis. Patient-derived xenograft (PDX) models derived from patients with either MLL-r acute myeloid leukemia or MLL-r acute lymphoblastic leukemia (ALL) showed dramatic reductions of leukemia burden when treated with VTP50469. Multiple mice engrafted with MLL-r ALL remained disease free for more than 1 year after treatment. These data support rapid translation of this approach to clinical trials.

Legend

Protein

Chemical

Disease

Primary Citation of related structures